Small Molecules

27 Jul 2021 Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem
26 Jul 2021 New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition
24 Jul 2021 Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia
23 Jul 2021 HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study of Oral Small Molecule HST5040 for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)
22 Jul 2021 Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
22 Jul 2021 Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
22 Jul 2021 VERQUVO® (vericiguat) Approved in the European Union
22 Jul 2021 IM Therapeutics Reports Positive Results in Safety, Tolerability and Mechanism of Action of Phase 1b Trial of Lead Drug IMT-002 in Type 1 Diabetes
21 Jul 2021 NIMIUM Therapeutics and Paraza Pharma form partnership to develop new medicines to treat cardiometabolic diseases (CMDs), obesity and type 2 diabetes
21 Jul 2021 FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes
20 Jul 2021 Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
20 Jul 2021 Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC)
20 Jul 2021 Elucida Oncology Submits IND Application for ELU-001 for the Treatment of Cancers Overexpressing Folate-Receptor Alpha
20 Jul 2021 Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
20 Jul 2021 Rain Therapeutics Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differentiated Liposarcoma and Provides Patient Update from Prior Clinical Program
20 Jul 2021 Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184
20 Jul 2021 Imbria Pharmaceuticals Announces Initiation of Enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the Safety, Tolerability, and Efficacy of IMB-1018972 (IMB-101) in Patients With Non-Obstructive Hypertrophic Cardiomyopathy
19 Jul 2021 Almirall receives European Commission approval of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis
19 Jul 2021 Cytokinetics Announces Positive Topline Results of Redwood-HCM
19 Jul 2021 Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
19 Jul 2021 U.S. FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)
19 Jul 2021 Ubix Therapeutics kicks off IND-enabling studies of Bruton’s tyrosine kinase degrader
16 Jul 2021 Status on FDA Advisory Committee vote on roxadustat in anaemia of chronic kidney disease
15 Jul 2021 Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation
15 Jul 2021 Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up